Core Viewpoint - The stock price of Gaoshi Medical (02407) has experienced fluctuations following its removal from the Hong Kong Stock Connect list, with a significant increase of 65.50% from May to September last year, but has since faced a decline of nearly 20% since December 22, raising questions about its upcoming performance in the 2025 annual report [1][2]. Group 1: Stock Performance - After being removed from the Hong Kong Stock Connect list, Gaoshi Medical's stock price initially rose, achieving a monthly "four consecutive increases" [1]. - The stock price saw a cumulative increase of 65.50% from May to September last year, but began a three-month period of sideways movement starting in mid-September [1]. - Since December 22, the stock has declined nearly 20%, effectively reversing all gains made since the mid-year report [1]. Group 2: Market Dynamics - On March 10, the adjustment of the Hong Kong Stock Connect list led to an average stock price drop of 14.24% for the excluded stocks, with Gaoshi Medical being one of them [1]. - Despite the stock's removal, the proportion of shares held by Hong Kong Stock Connect investors has only decreased by 3% over the past 10 months, indicating limited selling pressure [2]. - The liquidity of Gaoshi Medical's stock has noticeably decreased post-removal, with monthly trading volumes dropping by 84.39% from February to April last year [4]. Group 3: Financial Performance - In 2024, Gaoshi Medical reported revenues of 1.428 billion yuan, a year-on-year increase of 1.6%, but net profit fell by 46.75% to 92.394 million yuan due to factors like currency fluctuations and goodwill impairment [7]. - The company has been attempting to adjust its business structure by increasing the proportion of self-owned products, but the revenue from agency products rebounded to 68.55% in 2024 [8]. - In the first half of 2025, Gaoshi Medical achieved revenues of 653 million yuan, a 1.7% increase year-on-year, with a gross profit margin of 48.3%, reflecting an improvement [9]. Group 4: Future Outlook - Analysts project that Gaoshi Medical's revenues will grow to 1.564 billion, 1.715 billion, and 1.875 billion yuan from 2025 to 2027, with corresponding net profits of 135 million, 180 million, and 214 million yuan [9]. - Following the release of the mid-year report, Gaoshi Medical's stock price surged by 19.31% over two days, indicating positive market sentiment towards its performance [9]. - The current trading volume and price movements suggest that the stock may be nearing a bottom, with potential for recovery as market conditions improve [10].

Core Viewpoint - The A-share market is experiencing fluctuations, with over 3,500 stocks in the red, while the Shanghai Composite Index shows a slight increase, indicating a mixed market sentiment [1] Market Performance - As of the midday close, the Shanghai Composite Index rose by 0.49%, and the Shenzhen Component Index increased by 0.09%. In contrast, the ChiNext Index fell by 0.37%, and the STAR Market 50 Index decreased by 0.73% [1] - The total trading volume across the Shanghai, Shenzhen, and Beijing markets reached approximately 1.93 trillion yuan [1] Sector Analysis - The pharmaceutical, automotive, and retail sectors experienced declines, while the oil, non-ferrous metals, coal, semiconductor, and brokerage sectors saw gains. Additionally, gold and disperse dye concepts were active [1] Investment Strategy - Dongguan Securities suggests that short-term indices may continue to fluctuate around moving averages, with an accelerated rotation of sectors. However, the spring market for A-shares is expected to continue, primarily characterized by structural trends [1] - Recommended investment strategies include balanced allocation, focusing on undervalued assets with stable earnings, technology sectors leading new productivity, and domestic demand expansion under the backdrop of a strong domestic market [1]

证券日报网讯1月27日，海南海药（000566）在互动平台回答投资者提问时表示，截至2026年1月20日公 司股东户数为132189户。 ...

切实加大保护力度，58案适用惩罚性赔偿，合计赔偿20.5亿元，案均超3500万元；超1000万元高额赔偿 案件73件，合计赔偿52.4亿元，案均近7200万元。 坚持"能改不发""能调尽调"，侵权、权属等民事实体案件二审改判率20.9%、调撤率37.7%，均明显高于 改革前。 有效服务保障新质生产力发展，7年来，受理涉战略性新兴产业案件6745件，占比从2019年的17.6%增 长到2025年的32.4%；受理专利等授权确权行政案件6543件，年均增长31.8%，其中发明专利授权确权 行政案件3704件，年均增长26.0%；受理发明专利侵权案件5354件，年均增长11.5%；受理涉标准必要 专利案件183件；受理药品专利链接案件41件；受理植物新品种案件923件，年均增长46.2%，2025年品 种权人胜诉率达90%。 经济观察网 据央视新闻客户端消息，今天（28日），最高人民法院召开新闻发布会，介绍2019年1月1 日最高法设立知识产权法庭以来，知识产权案件审理情况。 据介绍，最高法知识产权法庭成立7年来，积极践行"保护知识产权就是保护创新"理念，在激励保障科 技创新、维护市场公平竞争、服务高水平对外开放、 ...

证券日报网讯1月27日，古汉医药（000590）在互动平台回答投资者提问时表示，根据《深圳证券交易 所股票上市规则》的相关规定，若公司满足业绩预告相应条件，公司将在会计年度结束后的一个月内对 年度经营情况进行业绩预告，并确定披露相关事宜。 ...

Group 1: Company Acquisition - Yingxin Development plans to acquire 60% stake in Guangdong Changxing Semiconductor Technology Co., Ltd. for cash of 520 million yuan [1][10] - After the acquisition, Changxing Semiconductor will become a subsidiary and included in the consolidated financial statements of Yingxin Development [1][10] - Changxing Semiconductor is expected to achieve revenues of 406 million yuan and 646 million yuan in 2024 and 2025, respectively, with net profits of 2.21 million yuan and 74.57 million yuan [1][10] Group 2: Strategic Direction - Yingxin Development has established a strategic direction to expand into the technology sector, aiming to quickly enter new markets with significant growth potential through acquisitions [2][11] - The company is optimistic about the long-term development prospects of the artificial intelligence and storage chip markets, which will help improve its business structure and asset portfolio [2][11] Group 3: Financial Performance and Market Activity - In January, 13 listed companies disclosed significant shareholder buyback plans, reflecting confidence in their operational development [5][14] - Among these companies, 12 disclosed minimum buyback amounts totaling 577 million yuan, with Meihua Biological, Puluo Pharmaceutical, and Jianzhijia leading in proposed buyback amounts [6][14] - The average stock price increase for these 13 companies in January was 14.37%, with notable gains from companies like Kaipu Biological and Oke Yi [7][17]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301331 证券简称：恩威医药 公告编号：2026-003 恩威医药股份有限公司 股东询价转让定价情况提示性公告 股东成都恩威投资（集团）有限公司保证向恩威医药股份有限公司提供的信息内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 根据2026年1月27日询价申购情况，初步确定的本次询价转让价格为26.54元/股； 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为26.54元/股。 （二）参与本次询价转让报价的机构投资者家数为30家，涵盖了基金管理公司、证券公司、保险公司、 私募基金管理人、合格境外投资者等专业机构投资者。参与本次询价转让报价的机构投资者合计有效认 购股份数量为16,476,000股，对应的有效认购倍数为4.12倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为11名机构投资者，拟受让股份总数为 4,000,000股。 二、相关风险提示 （一）本次询价转让受让 ...

1月27日，深圳市罗湖区第八届人民代表大会第八次会议开幕，罗湖区人大代表、深圳市星银医药有限 公司工会主席、宣传部经理王红表示，作为一名长期就职于企业的代表，我深刻地感受到近年来罗湖区 加大力度构建全周期、全覆盖、全链条的企业服务体系，取得了显著成效，特别是推行惠企护航工 程，"一企一策"精准服务机制，使助企、惠企工作更加主动、更有实效，极大地提升了企业办事效率。 在产业要素保障方面，罗湖区积极破解土地、资金、人才等瓶颈，通过城市更新释放产业空间、人才房 保障、实施"菁英人才"计划等举措，为产业发展提供有力支撑。 在挖掘和创新利用辖区的生态文化资源上，王红建议从三个方面着手，一是生态资源的"价值转化"，我 们不能仅仅停留在保护层面，而是要考虑如何让绿水青山成为惠及市民的"金山银山"。比如梧桐山，可 以大力发展徒步、登山等旅游产业，打造精品生态旅游线路；二是文化资源的"活化利用"，对于改革开 放历史遗存，建议通过数字化手段，沉浸式体验等方式，让历史"活"起来、"动"起来。东门老街和莲塘 国威路要在保留城市烟火气的基础上，引入新业态、新模式，推动传统商业街区向时尚消费、文化体验 街区转型。同时，要充分利用深港地缘 ...

*ST三圣1月27日公告，预计2025年度实现营业收入9.1亿元-10.7亿元，上年同期营业收入119,571.82万 元。预计2025年度归属于上市公司股东的净利润亏损3.8亿元-5.3亿元，上年同期亏损65,013.06万元。报 告期内，受资金紧张、外部市场环境变化等因素影响，建材板块和医药板块业绩均有不同程度下降；鉴 于公司重整方案未豁免子公司对其借款所提供的连带责任保证，相关债权将按重整计划予以处理。根据 企业会计准则的谨慎性原则，公司对该项可能发生的担保损失计提了预计负债；公司结合医药公司实际 经营情况及行业市场变化等影响，根据相关规定，公司对可能发生减值损失的资产计提减值准备。 ...

Group 1 - The core investment philosophy of the company is based on the framework of "macro first, mid-level capturing prosperity, micro digging for leaders" and follows the "four good" principles: good industry, good phase, good company, and good price [1][2] - The company emphasizes the importance of macroeconomic data and policies, adjusting positions and styles dynamically to respond to changes in the macro environment [1] - The company identifies key investment areas in the current era of technological advancement, focusing on artificial intelligence, advanced manufacturing, new consumption, and pharmaceuticals as mid-to-long-term investment priorities [1] Group 2 - The company believes that selecting a "good industry" can sometimes be more important than choosing a "good company," as it provides opportunities for significant beta returns [2] - The "good phase" refers to periods of upward industry prosperity and accelerating performance growth, while cautioning against sectors with high valuations that may have over-leveraged growth [2] - In terms of portfolio management, the company emphasizes balanced industry allocation and flexible rotation to capture high prosperity opportunities while diversifying to reduce portfolio volatility [2]